China Resources Pharmaceutical Group Limited (HKG:3320)
Hong Kong · Delayed Price · Currency is HKD 4.950
+0.010 (0.20%)
Sep 10, 2025, 4:08 PM HKT
HKG:3320 Revenue
China Resources Pharmaceutical Group had revenue of 131.87B CNY in the half year ending June 30, 2025, with 7.37% growth. This brings the company's revenue in the last twelve months to 260.94B, up 4.18% year-over-year. In the year 2024, China Resources Pharmaceutical Group had annual revenue of 257.67B with 5.30% growth.
Revenue (ttm)
260.94B CNY
Revenue Growth
+4.18%
P/S Ratio
0.11
Revenue / Employee
3.59M CNY
Employees
72,700
Market Cap
31.04B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.67B | 12.97B | 5.30% |
| Dec 31, 2023 | 244.70B | 26.52B | 12.16% |
| Dec 31, 2022 | 218.18B | 25.26B | 13.10% |
| Dec 31, 2021 | 192.92B | 24.16B | 14.31% |
| Dec 31, 2020 | 168.76B | -14.00B | -7.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| WuXi Biologics | 21.98B |
| Akeso | 2.75B |
| CSPC Pharmaceutical Group | 28.49B |
China Resources Pharmaceutical Group News
- 1 year ago - Health product chain store CR Care to close all 19 branches in Hong Kong in November - Hong Kong Free Press